Gyre Therapeutics, Inc.
GYRE
$8.11
$0.354.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 104.84% | 108.27% | 113.00% | -2,033.69% | -3,059.62% |
| Total Depreciation and Amortization | 82.22% | 35.80% | 40.75% | 52.90% | 36.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -93.75% | -94.22% | -94.49% | 515.81% | 397.31% |
| Change in Net Operating Assets | -60.53% | -676.24% | -236.70% | -2,262.89% | -59.00% |
| Cash from Operations | -88.88% | -136.24% | -114.06% | -88.66% | -39.43% |
| Capital Expenditure | 83.19% | 68.51% | 72.82% | 41.94% | 25.71% |
| Sale of Property, Plant, and Equipment | -80.95% | -50.70% | -39.61% | -13.48% | 495.52% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 76.06% | 50.70% | -6.94% | -17.15% | -87.62% |
| Cash from Investing | 72.05% | 44.67% | -0.63% | 25.68% | -7.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,815.54% | 423.56% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,764.71% | -- | -- | -1,452.00% | -583.74% |
| Cash from Financing | 653.86% | -11.72% | -15.92% | 2,980.44% | 1,324.76% |
| Foreign Exchange rate Adjustments | -117.99% | 67.46% | 8.39% | 114.45% | 110.73% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 367.32% | -998.23% | -360.33% | -477.43% | -12.36% |